CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

I’ve been living with depression for almost 12 years. I’m 31 now and I found out I had major depressive disorder when I was 19. I had a miserable freshman year of college, but I didn't really ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

Major depressive disorder (MDD) is a debilitating mental health condition characterized by persistent low mood, loss of ...

A team of US-based scientists have found "a probable causal connection" between a form of bacteria found in the human gut and the onset of depression.Carried out by a team from Harvard University and ...

The largest, most ethnically diverse, study of its kind has flagged hundreds of genetic variants that play a role in ...

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...

Neurocrine Biosciences advances Phase 3 plans for osavampator after achieving Phase 2 success in major depressive disorder, amending its Takeda deal.

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

Biochemical analyses provide an answer to the question of how the gut bacterium Morganella morganii might contribute to some ...

Neurocrine Biosciences amended its agreement with Takeda Pharmaceutical regarding the development and commercialization of osavampator, a treatment for major depressive disorder.

The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...